Phio Pharmaceuticals (PHIO) vs Theriva Biologics (TOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Theriva Biologics (TOVX) has outperformed Phio Pharmaceuticals (PHIO) over the past year, losing 49.5% versus a loss of 59.8%. Over five years, PHIO leads with a -99.5% price change compared with -99.8% for TOVX. Phio Pharmaceuticals is the larger company by market cap ($11.3 million vs $10.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHIO | TOVX |
|---|---|---|
| Share price | $0.9731 | $0.2271 |
| Market cap | $11.30M | $10.42M |
| 1-day change | -2.69% | -2.95% |
| YTD return | -7.32% | +8.14% |
| 1-year return | -59.79% | -49.53% |
| 5-year return | -99.46% | -99.79% |
| P/E ratio (TTM) | — | 0.31 |
| EPS (TTM) | $-1.29 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.19 | $0.86 |
| 52-week low | $0.813 | $0.16 |
| Distance from 52-week high | -76.78% | -73.59% |
| Analyst consensus | none | none |
| Avg. price target upside | +1338.70% | +1000.84% |
| Average volume | 582.32K | 530.02K |
| Shares outstanding | 11.62M | 45.89M |
| Employees | 6 | 15 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TOVX has outperformed PHIO by 10.3 percentage points over the past year.
About Phio Pharmaceuticals
PHIO stock →Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Healthcare · Biotechnology · 6 employees
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Healthcare · Biotechnology · 15 employees
PHIO vs TOVX FAQ
Which is bigger, Phio Pharmaceuticals or Theriva Biologics?
Phio Pharmaceuticals (PHIO) is larger, with a market capitalization of $11.30M compared with $10.42M for Theriva Biologics (TOVX).
Which stock has performed better over the past year, PHIO or TOVX?
TOVX returned -49.53% over the past 12 months, compared with -59.79% for PHIO (price return, excluding dividends). Past performance does not predict future results.
Are Phio Pharmaceuticals and Theriva Biologics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.